Want to see ANTX full AI Analyst Report?
AN2 Therapeutics, Inc. (ANTX) Ratios
AN2 Therapeutics, Inc. Ratios
ANTX's free cash flow for Q2 2026 was $-7.00M. For the 2026 fiscal year, ANTX's free cash flow was increased by $0.00 and operating cash flow was $-7.00M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.87 | 8.43 | 7.87 | 13.72 | 17.70 |
| Quick Ratio | 6.87 | 8.43 | 7.87 | 13.72 | 17.70 |
| Cash Ratio | 2.29 | 2.09 | 1.11 | 3.79 | 3.56 |
| Solvency Ratio | -3.96 | 0.32 | 0.35 | -5.69 | -6.32 |
| Operating Cash Flow Ratio | -3.42 | -4.81 | -3.79 | -4.66 | -6.03 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 51.05M | $ 76.02M | $ 96.46M | $ 91.43M | $ 56.70M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.17 | 1.13 | 1.11 | 1.08 | 1.06 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -79.53 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -82.22 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
| Net Debt to EBITDA | 0.57 | -6.60 | -3.19 | 0.66 | 0.56 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 92.30% | 94.07% | 92.96% | 96.91% | 99.86% |
| Return on Assets (ROA) | -56.78% | -55.73% | -46.66% | -39.93% | -32.98% |
| Return on Equity (ROE) | -66.29% | -62.70% | -51.91% | -42.94% | -34.80% |
| Return on Capital Employed (ROCE) | -71.59% | -66.65% | -55.84% | -44.31% | -34.84% |
| Return on Invested Capital (ROIC) | -71.59% | -66.65% | -55.84% | -44.29% | -34.84% |
| Return on Tangible Assets | -56.78% | -55.73% | -46.66% | -39.93% | -32.98% |
| Earnings Yield | -102.11% | -124.68% | -13.39% | -28.02% | -7.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -10058.83 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 10058.83 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.99 | -1.65 | -2.26 | -2.18 | -1.09 |
| Free Cash Flow Per Share | -0.99 | -1.65 | -2.26 | -2.18 | -1.09 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -631.36 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -86.61% | -119.66% | -11.02% | -22.89% | -7.10% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.98 | -0.80 | -7.47 | -3.57 | -13.40 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 0.65 | 0.50 | 3.88 | 1.53 | 4.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.15 | -0.84 | -9.07 | -4.37 | -14.09 |
| Price-to-Operating Cash Flow Ratio | -1.15 | -0.84 | -9.07 | -4.37 | -14.09 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.02 | 4.17 | -0.04 | -0.15 |
| Enterprise Value Multiple | -0.41 | 6.13 | 95.43 | -2.91 | -12.82 |
| Enterprise Value | 14.50M | 19.81M | 467.92M | 119.02M | 276.50M |
| EV to EBITDA | -0.41 | 6.13 | 95.43 | -2.91 | -12.82 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.49 | -0.40 | -8.78 | -3.56 | -13.50 |
| EV to Operating Cash Flow | -0.49 | -0.40 | -8.78 | -3.56 | -13.50 |
| Tangible Book Value Per Share | 1.76 | 2.74 | 5.28 | 6.22 | 3.30 |
| Shareholders’ Equity Per Share | 1.76 | 2.74 | 5.28 | 6.22 | 3.30 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.16 | -1.72 | -2.74 | -2.67 | -1.15 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 0.96 | 0.82 | 0.82 | 0.95 |
Currency in USD
